Sagimet Biosciences (SGMT) Expected to Announce Earnings on Thursday

Key Points

• Sagimet Biosciences will report Q1 2026 results before the market opens on Thursday, May 14, with analysts expecting a loss of about ($0.3709) EPS
• Despite near‑term losses, Wall Street sentiment is bullish: Sagimet has a consensus rating of “Moderate Buy” with an average target of $28.63 (several firms raised targets, including Canaccord to $49), while the stock recently jumped ~8.5% to $8.38 and carries a market cap of ~$273M and a high beta (3.60).

Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) will likely be releasing its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect Sagimet Biosciences to post earnings of ($0.3709) per share for the quarter. Interested persons may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 14, 2026 at 9:30 AM ET.

Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) last announced its quarterly earnings data on Wednesday, March 11th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.14. On average, analysts expect Sagimet Biosciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sagimet Biosciences Stock Up 8.5%

Shares of Sagimet Biosciences stock opened at $8.38 on Thursday. The stock's 50-day simple moving average is $5.80 and its 200-day simple moving average is $6.28. Sagimet Biosciences has a 52 week low of $3.08 and a 52 week high of $11.41. The company has a market capitalization of $273.02 million, a price-to-earnings ratio of -5.34 and a beta of 3.60.

Wall Street Analyst Weigh In

Several brokerages have recently commented on SGMT. Canaccord Genuity Group boosted their price objective on Sagimet Biosciences from $28.00 to $49.00 and gave the company a "buy" rating in a research report on Monday. Rodman & Renshaw started coverage on Sagimet Biosciences in a report on Thursday, March 26th. They issued a "buy" rating and a $28.00 target price on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Sagimet Biosciences in a report on Tuesday, April 21st. Oppenheimer reaffirmed an "outperform" rating on shares of Sagimet Biosciences in a research note on Friday, May 1st. Finally, Wall Street Zen upgraded Sagimet Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday, March 14th. Nine analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Sagimet Biosciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $28.63.

Trending Headlines about Sagimet Biosciences

Here are the key news stories impacting Sagimet Biosciences this week:

• Positive Sentiment: HC Wainwright raised multiple 2026 quarter and full‑year EPS estimates and materially increased long‑range forecasts (FY2027–FY2030), while maintaining a Buy rating and a $29 price target — a clear analyst catalyst that can drive investor demand. HC Wainwright raises estimates, Buy $29 target
• Positive Sentiment: A Zacks piece highlights that the mean of analysts' price targets implies ~241.8% upside from current levels, drawing attention to significant upside implied by street estimates — this can attract speculative and momentum investors. Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?
• Positive Sentiment: Zacks also ran a momentum‑style piece framing SGMT as a strong momentum stock — coverage like this can amplify buying interest from traders focused on short‑term strength. Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?
• Neutral Sentiment: Near‑term fundamentals remain a constraint: consensus still shows negative EPS for FY2026 (around -$1.48 to -$1.51), so the story is driven by future profitability expectations and pipeline/strategy execution rather than current earnings. Recent quarterly results (March quarter) did beat estimates, which supports the bullish narrative but doesn’t eliminate short‑term reported losses. MarketBeat Sagimet overview

Insider Buying and Selling

In related news, CEO David Happel sold 12,101 shares of Sagimet Biosciences stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $5.36, for a total value of $64,861.36. Following the completion of the transaction, the chief executive officer owned 677,621 shares in the company, valued at approximately $3,632,048.56. This trade represents a 1.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 14.70% of the company's stock.

Hedge Funds Weigh In On Sagimet Biosciences

Institutional investors and hedge funds have recently modified their holdings of the stock. Royal Bank of Canada boosted its holdings in shares of Sagimet Biosciences by 819.2% in the 4th quarter. Royal Bank of Canada now owns 4,927 shares of the company's stock worth $29,000 after purchasing an additional 4,391 shares during the period. Bank of America Corp DE boosted its holdings in shares of Sagimet Biosciences by 81.8% in the 2nd quarter. Bank of America Corp DE now owns 9,943 shares of the company's stock worth $76,000 after purchasing an additional 4,473 shares during the period. Virtu Financial LLC purchased a new position in shares of Sagimet Biosciences in the 4th quarter worth approximately $62,000. Jefferies Financial Group Inc. purchased a new position in shares of Sagimet Biosciences in the 3rd quarter worth approximately $95,000. Finally, LPL Financial LLC boosted its holdings in shares of Sagimet Biosciences by 31.3% in the 4th quarter. LPL Financial LLC now owns 20,574 shares of the company's stock worth $122,000 after purchasing an additional 4,899 shares during the period. Hedge funds and other institutional investors own 87.86% of the company's stock.

About Sagimet Biosciences

Sagimet Biosciences NASDAQ: SGMT is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company's lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101's potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.